Stupak Evgeny V, Veryasikina Yulia A, Titov Sergey E, Askandaryan Arsen S, Hiana James C, Zhimulyov Igor F, Stupak Vyacheslav V
Department of Neurosurgery, Novosibirsk Research Institute of Traumatology and Orthopedics n.a. Ya.L. Tsivyan, Novosibirsk, RUS.
Laboratory of Genetics, Institute of Molecular and Cell Biology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, RUS.
Cureus. 2023 Mar 8;15(3):e35906. doi: 10.7759/cureus.35906. eCollection 2023 Mar.
The study of brain tumors has shown that microRNAs can act as both oncogenes and tumor suppressors and, consequently, can be used as biomarkers for the diagnosis and prognosis of such tumors. Thus, big interest arises in the role of microRNA and its part in oncogenesis in the human brain to find key molecules that can act as tumor markers for diagnostic and prognostic purposes, as well as potential therapeutic agents.
The sim of this study was to assess histological, molecular, and genetic metrics in patients with supratentorial gliomas, and indicate diagnostic and prognostic abilities of microRNA usage as biomarkers of the grade of malignancy of the tumor.
Clinical and genetic studies were performed in 107 operated patients with supratentorial gliomas of different malignancies. The expression levels of 10 microRNAs (-16, -21¸ -31, -124, - 125b, -181b, -191, -221, -223, and -451) were analyzed using real-time polymerase chain reaction (PCR). The results were analyzed statistically using Statistica 12.0 (Statistica, Hamburg, Germany) and GraphPad Prism 9 software (GraphPad Software Inc., Boston, Massachusetts, United States).
Based on a comprehensive statistical analysis involving the database of the clinical results of treatment of all 107 patients (combined treatment methods, quality of life, and survival) and microRNA expression levels, specific profiles of microRNA expression typical of different histotypes of gliomas of different malignancy were identified, the prognostic significance of the studied microRNAs as potential predictors of survival in patients with brain gliomas was determined, and microRNAs with the highest prognostic value were identified among them.
对脑肿瘤的研究表明，微小RNA既可以作为癌基因，也可以作为肿瘤抑制因子，因此可以用作此类肿瘤诊断和预后的生物标志物。因此，人们对微小RNA在人脑肿瘤发生中的作用产生了浓厚兴趣，以寻找可作为诊断和预后肿瘤标志物的关键分子，以及潜在的治疗药物。
本研究的目的是评估幕上胶质瘤患者的组织学、分子和遗传指标，并指出使用微小RNA作为肿瘤恶性程度生物标志物的诊断和预后能力。
对107例接受手术的不同恶性程度幕上胶质瘤患者进行了临床和基因研究。使用实时聚合酶链反应（PCR）分析了10种微小RNA（-16、-21、-31、-124、-125b、-181b、-191、-221、-223和-451）的表达水平。使用Statistica 12.0（德国汉堡的Statistica公司）和GraphPad Prism 9软件（美国马萨诸塞州波士顿的GraphPad软件公司）对结果进行统计学分析。
基于对所有107例患者的临床治疗结果（联合治疗方法、生活质量和生存率）数据库以及微小RNA表达水平的综合统计分析，确定了不同恶性程度胶质瘤不同组织学类型典型的微小RNA表达特异性谱，确定了所研究的微小RNA作为脑胶质瘤患者生存潜在预测指标的预后意义，并从中确定了具有最高预后价值的微小RNA。
